The inhibition of cancer cell growth via combination therapy of ETP with the aid of siPIK3CA delivered by single as well as dual functional peptides-modified nanoparticles was investigated in CD133(+) H69 cells serving as an ETP-resistant SCLC cell model. The gene discussed is PROM1; the disease is small cell lung carcinoma.